Fungal, bacterial and viral infections in hematology
Overview of Presentations with access to videos on demand (EHA subscription needed)
LINKS TO ABSTRACTS:
(S280) DEVELOPMENT OF NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 IN HEALTHY SANITARY WORKERS AND OCTOGENARIANS POST-BNT162B2 MRNA COVID-19 VACCINE: FIRST RESULTS OF A PROSPECTIVE TRIAL IN 366 INDIVIDUALS
Presenter: Evangelos Terpos, Athens, Greece
The study authors conclude that the BNT162b2 mRNA vaccine is exceedingly effective in producing high anti-SARS-CoV-2 antibody (NAbs and anti-spike RBD IgGs) titers in healthy donors. Given however that this readout is seemingly (up to the delivery of the second dose of the vaccine) age-dependent, the authors suggest that the second timely vaccination is needed, especially in the elderly population.
Presentation ID p436-2
(S281) EHA GUIDELINE: ANTIFUNGAL PROPHYLAXIS IN ACUTE MYELOID LEUKEMIA TREATED WITH NOVEL AGENTS
Presenter: Jannik Stemler, Köln, Germany
The study authors conclude that this guideline document to help supporting the decision if to use antifungal prophylaxis in AML patients under treatment with novel agents will soon become available. It is the first one assessing this specific setting and will complement existing guidelines for antifungal prophylaxis.
Presentation ID p436-3
(S282) RATIONAL: A RANDOMISED CONTROLLED FEASIBILITY TRIAL COMPARING PROPHYLACTIC IMMUNOGLOBULIN WITH ANTIBIOTICS IN PATIENTS WITH ACQUIRED HYPOGAMMAGLOBULINEMIA SECONDARY TO HAEMATOLOGICAL MALIGNANCIES
Presenter: Zoe McQuilten, Australia
The study authors conclude that in this phase II trial, a similar proportion of patients allocated to Ig and to prophylactic oral antibiotics remained alive and on their assigned treatment arm at 12 months. There was no significant difference in time to first major infection between the two treatment arms. The authors support the feasibility of proceeding with a phase III trial to compare efficacy, safety, and cost-effectiveness of Ig replacement to prophylactic oral antibiotics in patients with acquired hypogammaglobulinemia.
Presentation ID p436-4
(S283) BASELINE CT THORAX AND RISK OF INVASIVE FUNGAL DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION
Presenter: Varun Mehra, United Kingdom
The study authors conclude that previous invasive fungal lung disease (IFD) history, EORTC changes & multiple non-EORTC changes at baseline CT and abnormal TLCO pre-HSCT influenced IFD related outcomes with a significant reduction survival post-IFD event. The authors suggest early respiratory optimization including focussed diagnostics in patients with abnormal pre-HSCT chest imaging, to reduce the risk of IFD-related mortality.
Presentation ID p436-5
(S284) EARLY INFECTIONS FOLLOWING COMMERCIAL ANTI-CD19 CAR-T CELLS INFIRM POPULATION – A SINGLE CENTER RETROSPECTIVE STUDY
Presenter: Ofrat Beyar-Katz, Israel
The study authors conclude that infections were common in the first month following CAR-T cell administration, however were not increased in elderly patients or those presenting with poorer PS. The authors recommend that patients refractory to bridging therapy and ICANS should be monitored cautiously for the occurrence of infections and CMV monitoring should also be considered.